MK-677 Dosage and Side Effects: What the Trials Measured

The MK-677 dosage question has an unusually direct answer, because this compound — unlike most things sold beside it — went through a real clinical program. The human trials dosed MK-677 at 10 to 50 mg by mouth once daily, and the overwhelming majority settled on 25 mg. The community's favorite range of 10 to 25 mg a day is, for once, roughly the range the science used. That is not the reassuring fact it sounds like, because the same trials measured what 25 mg a day does to a body: fasting blood glucose went up, insulin sensitivity went down, appetite spiked, fluid collected in the lower legs, and one placebo-controlled trial in older patients was terminated early over a congestive heart failure safety signal — the specific event the FDA now cites when it flags ibutamoren as a significant safety risk. The side-effect profile is not folklore. It is the best-documented thing about this drug.

This page covers the doses the trials actually used and what happened at those doses. For the efficacy verdict — hormones up, strength flat — see our full MK-677 evidence review; this article is the dosing-and-safety half of that story.

MK-677 Is Not a Peptide, and It Is Not an Approved Drug

Two facts frame everything below. First, MK-677 (ibutamoren) is not a peptide at all: it is a small, orally active, non-peptide ghrelin mimetic — it activates the same receptor as the hunger hormone ghrelin and makes your own pituitary release growth hormone in larger pulses¹². No injections, no reconstitution — a tablet or a liquid, which is most of its appeal on a site otherwise full of injectables. It is usually sold alongside SARMs by the same vendors, and it gets lumped in with them; how the two families actually differ is covered in peptides vs SARMs for recovery.

Second, no regulator anywhere has approved an MK-677 product for any use. Merck ran the development program in the 1990s and 2000s and it did not end in a drug. Our peptide FDA status tracker records the current U.S. position: ibutamoren mesylate sits in category 2 — significant safety risk — under both of FDA's interim compounding policies, the only compound on our tracker flagged under both, placed there on the 503B side in December 2022 and on the 503A side in September 2023. FDA's stated reason is not generic caution: the agency points to a randomized trial in patients recovering from hip fracture that was terminated early over a potential congestive heart failure signal¹³. That means no U.S. pharmacy may legally compound it, so every bottle sold to consumers is a gray-market research chemical. Keep that in mind through every number that follows: the doses below were given as pharmaceutical-grade material under medical monitoring, which is not what anyone is buying today.

What Doses Did the MK-677 Trials Actually Use?

The clinical program tested a fairly narrow band of doses, and it converged fast.

• •2, 10, and 25 mg once daily in the dose-ranging study in healthy adults aged 64 to 81. The response was dose-dependent: 25 mg raised mean 24-hour growth hormone concentration by 97% and pushed IGF-1 from 141 to 265 micrograms per liter over four weeks — back into the range of young adults¹.
• •5 and 25 mg at bedtime in healthy young men for 7 days, where IGF-1 rose dose-dependently², and the same doses in the sleep study³.
• •25 mg once daily in essentially every efficacy trial: the diet-induced catabolism study⁴, the 8-week study in obese men⁵, the 12-to-18-month osteoporosis trial⁷, the one-year body-composition trial in healthy older adults⁸, both hip-fracture trials⁹¹⁰, and the 12-month Alzheimer's trial¹¹.
• •50 mg once daily appears once, briefly: a bone-turnover study stepped 30 healthy elderly subjects from 25 mg for two weeks to 50 mg for two weeks⁶. No long-term trial used it.

So when a forum protocol says 10 to 25 mg a day, it is not inventing numbers the way BPC-157 protocols invent theirs — it is quoting the trial range. The honest difference is what the trials found at that range, and the fact that a research-chemical bottle gives you none of the things that made those trials tolerable: verified drug content, glucose monitoring, and an ethics board watching the safety data.

The Side Effects Were Measured, Not Rumored

The one-year randomized trial in 65 healthy adults aged 60 to 81 — the single best safety dataset — recorded the profile directly at 25 mg daily: the most frequent side effects were an increase in appetite that subsided within a few months, and transient, mild lower-extremity edema and muscle pain⁸. The appetite effect is mechanism, not accident — MK-677 works by switching on the hunger hormone's receptor². The same trial found body weight rose 2.7 kg on MK-677 against 0.8 kg on placebo, and cortisol went up⁸. In the osteoporosis trial that ran MK-677 for 12 to 18 months in nearly 300 older women, growth-hormone-mediated side effects were likewise noted, though discontinuations for adverse events were relatively infrequent⁷.

Does MK-677 Raise Blood Sugar?

Yes — this is the finding that shows up in study after study, and it is the honest headline of the compound.

• •In the dose-ranging trial in healthy elderly adults, four weeks of MK-677 raised fasting glucose from 5.4 to 6.8 mmol/L — roughly 97 to 122 mg/dL, which is movement from normal into diabetes-range territory for a fasting reading¹.
• •In the one-year trial, fasting glucose rose a more modest 0.3 mmol/L (5 mg/dL) — but insulin sensitivity decreased⁸.
• •In obese men treated for 8 weeks, fasting values held steady while an oral glucose tolerance test showed impaired glucose homeostasis at both 2 and 8 weeks⁵ — the deterioration was visible as soon as the body was challenged with sugar.
• •The effect is a class property, not an MK-677 quirk: a two-year trial of capromorelin, a related oral growth hormone secretagogue, in 395 older adults was itself terminated early and recorded small increases in fasting glucose, glycosylated hemoglobin, and indices of insulin resistance¹².

Growth hormone is a counter-regulatory hormone — it opposes insulin. Anything that raises GH around the clock pushes glucose metabolism the wrong way, and for anyone with prediabetes, diabetes, or a family history of either, that is a real cost being taken on for a compound whose strength and performance benefits never materialized in trials⁸.

The Trial That Was Stopped

The heart-failure signal deserves its own account, because it is the reason MK-677 carries FDA's harshest compounding flag. Two placebo-controlled trials gave 25 mg daily to older patients recovering from hip fracture. The first, in 161 patients, raised IGF-1 by 84% but produced no statistically significant improvement in functional recovery — and it had excluded patients with congestive heart failure from enrolling at all⁹. The second, a phase IIb trial in 123 patients, was terminated early due to a safety signal of congestive heart failure in a limited number of patients; its authors concluded MK-677 "has an unfavorable safety profile in this patient population"¹⁰. FDA's category-2 listing for ibutamoren cites exactly this potential for congestive heart failure¹³. GH-axis activation retains sodium and water — the same mechanism behind the ankle edema in healthy adults — and in a frail heart, that fluid load matters. A young lifter is not an 80-year-old hip-fracture patient, but the mechanism travels with the molecule.

It is worth adding that the failures were not confined to frail hearts. The 12-month Alzheimer's trial in 563 patients raised IGF-1 by 72.9% and changed no clinical outcome at all¹¹. Marker up, outcome flat, is this compound's signature — the pattern our growth hormone peptides and recovery review documents across the whole class.

The Sleep Effect Is Real — and Small-Study Real

The one commonly claimed benefit with direct trial support is sleep architecture. In a crossover study, 25 mg at bedtime increased stage IV (deep) sleep by about 50% and REM sleep by more than 20% in young men, and increased REM by nearly 50% in older adults³. Those are striking numbers from small groups — eight young and six older subjects — so they deserve the "promising, not proven" label rather than the certainty the marketing gives them. The wider field of sleep-marketed compounds is covered in peptides for sleep. Bedtime dosing, which the community treats as folklore wisdom, is simply how the trials administered it²³.

What a Buyer Actually Gets Is the Other Half of "Dosage"

Every number above assumes the tablet contains what the label says. Nothing sold as MK-677 today carries that assurance: with no approved product and no lawful compounding route, supply is research-chemical vendors whose identity, purity, and actual milligram content are unverified — the problems laid out in how to verify a peptide COA, peptide vendor red flags, and the research-chemical gray zone. A "25 mg" capsule from an unverified vendor is a number on a label, not a dose. There is no prescriber-supervised route for MK-677 anywhere; the nearest legally prescribed relatives are the GHRH-analog programs, where real published prices exist — CoreAge Rx sells sermorelin from $99 a month with no membership fee and upfront pricing stated on the product page, while Invigor Medical prices sermorelin at $220.50 for 8 mg with the consult and supplies inside the number, billed every four weeks — which is thirteen charges in a calendar year, not twelve. Those routes have their own evidence problems, covered in sermorelin dosage and the injectable secretagogue comparison — but at least the vial contents and the recurring bill are knowable.

The popular "8 to 12 weeks on, then off" cycling advice has no trial behind it either — the studies ran continuous daily dosing for up to 18 months, and intermittent use has never been studied⁷⁸. Why on/off folklore persists anyway is covered in peptide cycling protocols.

Tested Athletes: Banned at Any Dose

MK-677 is prohibited by WADA under class S2 — peptide hormones, growth factors, related substances and mimetics — at all times, in and out of competition, as a growth hormone secretagogue¹⁴. There is no minimum dose and no off-season exception, and WADA-accredited laboratories have validated urinary assays for GH secretagogues, so it is a compound that screens can actually find — the practical detection picture is in do peptides show up on drug tests. You can confirm its status, and anything else you are considering, in our WADA prohibited-substance checker or the full WADA prohibited peptides list; the legal-versus-tested-sport distinction for the whole class is in are GH peptides safe and legal.

Bottom Line

MK-677's trials dosed 10 to 50 mg and almost always 25 mg once daily, so the community range is genuinely the trial range — and the trial record at that range is exactly why caution is warranted. At 25 mg a day, studies measured raised fasting glucose, impaired glucose tolerance, reduced insulin sensitivity, appetite spikes, edema, and — in older patients — a heart-failure signal that stopped a trial and now anchors FDA's significant-safety-risk listing^1581013. What the same trials did not find was the payoff: strength and physical function did not improve in a full year of treatment⁸. Where recovery compounds stand relative to each other is ranked in our best recovery peptides guide, and the muscle-specific picture is in peptides for muscle growth.

This article is educational, not medical advice. MK-677 is an unapproved compound with measured metabolic effects; anyone considering it — and especially anyone with any glucose abnormality or cardiac history — should be talking to a clinician, not a vendor.